AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24343267 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no SCPs)
Number of subjects: 38
Study 24343267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SCP and Control)
Number of subjects: 38
Study 23054970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 25
Study 23054970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20428722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (EP) consisting of aerobic exercise sessions at 50% to 70% of VO2 peak for 30 to 60 minutes, three times a week for three months
Number of subjects: 111
Study 20428722 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no exercise program
Number of subjects: 111
Study 18201935 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine (5 mg)
Number of subjects: 0
Study 18201935 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 mg)
Number of subjects: 0
Study 18201935 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (4 mg)
Number of subjects: 0
Study 15734854 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg daily for 12 weeks)
Number of subjects: 28
Study 12551868 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (24-hour infusion)
Number of subjects: 7800
Study 12551868 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion)
Number of subjects: 7800
Study 12551868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7800
Study 12551868 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion) in patients with negative troponin
Number of subjects: 7800
Study 12551868 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion) in patients with elevated C-reactive protein
Number of subjects: 7800
Study 10383508 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for 14 days (OC14 group)
Number of subjects: 145
Study 10383508 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 7 days (OCA7 group)
Number of subjects: 145
Study 8905708 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-endorphin
Number of subjects: 7
Study 8905708 — intervention group
Group type: EXPERIMENTAL
Intervention: Metenkephalin
Number of subjects: 7
Study 1676617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (needle inserted into Zusanli (St.36) and Sanyinjiao (Sp. 6) points at 12‐24 h after operation)
Number of subjects: 39
Study 1676617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 39
Study 1676617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39
Study 1676617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 6831755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole alone or in combination with systemic antibiotics
Number of subjects: 33
Study 6831755 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 33
Study 30730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MP (300 mg pregabalin orally + IV magnesium sulfate 50 mg/kg)
Number of subjects: 120
Study 30730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (300 mg pregabalin orally + placebo IV infusion)
Number of subjects: 120
Study 30730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M (placebo capsule + IV magnesium sulfate 50 mg/kg)
Number of subjects: 120
Study 30730476 — intervention group
Group type: COMPARATOR
Intervention: Group C (placebo capsule + placebo IV infusion)
Number of subjects: 120
Study 29988310 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week strength and conditioning program
Number of subjects: 0
Study 29988310 — intervention group
Group type: COMPARATOR
Intervention: 12-week walking program
Number of subjects: 0
Study 27321385 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin twice daily
Number of subjects: 33
Study 27321385 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sitagliptin once daily
Number of subjects: 33
Study 24560392 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety-engineered blood gas syringes
Number of subjects: 550
Study 24560392 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparinized syringes
Number of subjects: 550
Study 22157740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with epinephrine
Number of subjects: 93
Study 22157740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine mixed with 0.5% bupivacaine
Number of subjects: 93
Study 22157740 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 93
Study 21054461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg) with Eurycoma longifolia (200 mg)
Number of subjects: 14
Study 21054461 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg) with placebo (Lactose)
Number of subjects: 14
Study 17352519 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin
Number of subjects: 0
Study 17352519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled capecitabine-based regimens
Number of subjects: 0
Study 14762352 — intervention group
Group type: EXPERIMENTAL
Intervention: Right coronary artery grafting
Number of subjects: 303
Study 14762352 — intervention group
Group type: COMPARATOR
Intervention: No right coronary artery grafting
Number of subjects: 303
Study 11750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 20
Study 11750894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9580647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (one dose)
Number of subjects: 1602
Study 9580647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (two doses)
Number of subjects: 1602
Study 9580647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (both regimens)
Number of subjects: 1602
Study 9580647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study 9580647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated, cold-adapted influenzavirus vaccine
Number of subjects: 1602
Study 8072261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole alone
Number of subjects: 107
Study 8072261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin combination
Number of subjects: 107
Study 8072261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 8072261 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 107
Study 8072261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 107
Study 8072261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 107
Study 8072261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin
Number of subjects: 107
Study 2647156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphetamine infusion (0.3 mg/kg)
Number of subjects: 12
Study 2647156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4889238 — intervention group
Group type: EXPERIMENTAL
Intervention: lincomycin hydrochloride (Mycivin)
Number of subjects: 22
Study 4889238 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 30670760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 ppm SAPM
Number of subjects: 0
Study 30670760 — intervention group
Group type: COMPARATOR
Intervention: 22,600 ppm fluoride varnish
Number of subjects: 0
Study 30670760 — intervention group
Group type: COMPARATOR
Intervention: Negative control, no treatment
Number of subjects: 0
Study 28719765 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ)
Number of subjects: 30
Study 28719765 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitrate (SN)
Number of subjects: 30
Study 28719765 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA)
Number of subjects: 30
Study 26015557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - categorized as PA0 (inactive), PA1 (one to two times per week), PA2 (more than two times per week)
Number of subjects: 18028
Study 26015557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 18028
Study 24279607 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet pellet (PP) plus bioabsorbable barrier membrane (BM)
Number of subjects: 11
Study 24279607 — intervention group
Group type: COMPARATOR
Intervention: Bioactive glass (BG) graft material with barrier membrane (BM)
Number of subjects: 11
Study 23095869 — intervention group
Group type: EXPERIMENTAL
Intervention: TUTI-16 vaccine
Number of subjects: 21
Study 23095869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19235040 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones daily
Number of subjects: 34
Study 19235040 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg isoflavones daily
Number of subjects: 34
Study 17702736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 12
Study 17702736 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 12
Study 17702736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren 150 mg and Valsartan 160 mg
Number of subjects: 12
Study 15380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium loading test in treated CD patients
Number of subjects: 77
Study 15380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium loading test in untreated CD patients
Number of subjects: 77
Study 15380898 — intervention group
Group type: COMPARATOR
Intervention: Magnesium loading test in control group
Number of subjects: 77
Study 15380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium concentration
Number of subjects: 77
Study 15380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte magnesium concentration
Number of subjects: 77
Study 15380898 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intake
Number of subjects: 77
Study 11465977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 0
Study 11465977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11465977 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 9813387 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg (OCM) given three times daily for 10 days
Number of subjects: 157
Study 9813387 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg and amoxicillin 1 g (OA) given twice daily for 14 days
Number of subjects: 157
Study 9813387 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM group
Number of subjects: 157
Study 9813387 — intervention group
Group type: COMPARATOR
Intervention: OA group
Number of subjects: 157
Study 8569256 — intervention group
Group type: EXPERIMENTAL
Intervention: Water injection at Qimen, Riyue, and Juque points
Number of subjects: 56
Study 8569256 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 56
Study 2146870 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead QRS voltage sum
Number of subjects: 1588
Study 2146870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon index
Number of subjects: 1588
Study 2146870 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-T alterations
Number of subjects: 1588
Study 747689 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at subanaesthetic concentration of 0.25% (end‐tidal)
Number of subjects: 10
Study 747689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 31081030 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic mental health stigma intervention (brief contact interventions over a 6-week period)
Number of subjects: 0
Study 31081030 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 0
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional delivery care
Number of subjects: 459
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Health center delivery
Number of subjects: 459
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 459
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of obstetric complications
Number of subjects: 459
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of complications during last birth
Number of subjects: 459
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Health centers vs health posts
Number of subjects: 459
Study 31100070 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized transportation availability
Number of subjects: 459
Study 28615622 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized measurement order of the Hadamard basis using deterministic acquisition for single-pixel imaging.
Number of subjects: 0
Study 28615622 — intervention group
Group type: COMPARATOR
Intervention: Conventional compressed sensing techniques (randomized sampling).
Number of subjects: 0
Study 26314625 — intervention group
Group type: EXPERIMENTAL
Intervention: NBP607 (cell culture-derived inactivated trivalent influenza vaccine)
Number of subjects: 1156
Study 26314625 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (AgrippalS1, egg-based subunit vaccine)
Number of subjects: 1156
Study 24820759 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial mono‐polar radiofrequency ablation
Number of subjects: 210
Study 24820759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐atrial mono‐polar radiofrequency ablation
Number of subjects: 210
Study 24820759 — intervention group
Group type: COMPARATOR
Intervention: Control group (valve replacement followed by amiodarone)
Number of subjects: 210
Study 22746145 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist and patient alliance ratings
Number of subjects: 203
Study 22746145 — intervention group
Group type: EXPERIMENTAL
Intervention: Session progress ratings
Number of subjects: 203
Study 22746145 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist experience
Number of subjects: 203
Study 22746145 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial circumstances at treatment start
Number of subjects: 203
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharin solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeter glucose + saccharin solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringin solution (500-ml intragastric infusion)
Number of subjects: 0
Study 19535679 — intervention group
Group type: COMPARATOR
Intervention: Water (volumetric control)
Number of subjects: 0
Study 17525598 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrawound infusion with 300 mg diclofenac
Number of subjects: 92
Study 17525598 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Number of subjects: 92
Study 17525598 — intervention group
Group type: COMPARATOR
Intervention: Local ropivacaine infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Number of subjects: 92
Study 15341554 — intervention group
Group type: EXPERIMENTAL
Intervention: ba wei di huang wan (BDW)
Number of subjects: 33
Study 15341554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11588535 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (10-20 mg, once daily)
Number of subjects: 241
Study 11588535 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg, once daily)
Number of subjects: 241
Study 11588535 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (ITT population)
Number of subjects: 241
Study 11588535 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (ITT population)
Number of subjects: 241
Study 11588535 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine
Number of subjects: 241
Study 11588535 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 241
Study 9681776 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 112
Study 9681776 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 112
Study 8136506 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldberg Scale
Number of subjects: 21
Study 2402413 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 20
Study 606789 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed split or whole bivalent influenza vaccine (A/New Jersey/76-A/Victoria/75)
Number of subjects: 46
Study 606789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31755809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg
Number of subjects: 96
Study 31755809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) 2.0 mg
Number of subjects: 96
Study 31755809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 30973651 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + Substance-Free Activity Session (SFAS)
Number of subjects: 0
Study 30973651 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + Relaxation Training
Number of subjects: 0
Study 30973651 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + SFAS
Number of subjects: 0
Study 30973651 — intervention group
Group type: COMPARATOR
Intervention: Single-session BMI
Number of subjects: 0
Study 30973651 — intervention group
Group type: COMPARATOR
Intervention: e-Chug
Number of subjects: 0
Study 30973651 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0
Study 27535276 — intervention group
Group type: EXPERIMENTAL
Intervention: Leech therapy (5 leeches applied to the affected knee, once every week for 3 weeks)
Number of subjects: 90
Study 27535276 — intervention group
Group type: COMPARATOR
Intervention: TENS therapy
Number of subjects: 90
Study 25987441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (AVS) [vitamins C (500 mg), E (400 IU), beta‐carotene (15,000 IU), zinc (7.5 mg), selenium (50 mg), copper (1 mg), and manganese (2.5 mg)] for 4 weeks
Number of subjects: 10
Study 25987441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 22776518 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral intake within 5 days postoperatively
Number of subjects: 0
Study 22776518 — intervention group
Group type: COMPARATOR
Intervention: Late oral intake starting from postoperative day 6
Number of subjects: 0
Study 22776518 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral intake
Number of subjects: 0
Study 22115622 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1500
Study 22115622 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium bare-metal stent (BMS)
Number of subjects: 1500
Study 19571713 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee participation
Number of subjects: 368
Study 19571713 — intervention group
Group type: COMPARATOR
Intervention: Experienced physician-only procedures
Number of subjects: 368
Study 16940981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (300 to 1,200 mg m(‐2) with FA/VB(12))
Number of subjects: 31
Study 16940981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (with FA/VB(12))
Number of subjects: 31
Study 16823517 — intervention group
Group type: EXPERIMENTAL
Intervention: Track embolization
Number of subjects: 43
Study 16823517 — intervention group
Group type: COMPARATOR
Intervention: No track embolization (Control)
Number of subjects: 43
Study 14573830 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and training from a health adviser in the management of C trachomatis for clinical staff for 6 months
Number of subjects: 0
Study 14573830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 10569685 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal walking exercise
Number of subjects: 0
Study 8707913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure hyperactive (HA) group
Number of subjects: 1479
Study 8707913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed hyperactive/conduct-disordered (HA + CD) group
Number of subjects: 1479
Study 8707913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure conduct-disordered (CD) group
Number of subjects: 1479
Study 8707913 — intervention group
Group type: COMPARATOR
Intervention: Normal (N) control group
Number of subjects: 1479
Study 1897349 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation anaesthesia (ESA)
Number of subjects: 100
Study 1897349 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anaesthesia (NLA)
Number of subjects: 100
Study 7088627 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaner restraint seat offered with staff demonstration at discharge
Number of subjects: 30
Study 7088627 — intervention group
Group type: COMPARATOR
Intervention: No loaner restraint seat and no emphasis on car safety
Number of subjects: 30
Study 29072514 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract (5 drops, three times a day for 8 weeks)
Number of subjects: 60